Study summary

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

Additional Study Details

Phase
3
Product
  • Mirabegron
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    91
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English
    Protocol
    Available Language(s): English
    Statistical Analysis Plan (SAP)
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for Open-label Phase 3 Study with Mirabegron in Children From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site LV37101
      Riga, Latvia, LV-1004
      Completed
      Site DK45001
      Aarhus N, Denmark, DK-8200
      Withdrawn
      Site TR90005
      Ankara, Turkey, 06100
      Completed
      Site LT37002
      Kaunas, Lithuania, LT-50009
      Completed
      Site TR90006
      Bursa, Turkey
      Completed
      Site PL48001
      Gdansk, Poland, 80803
      Completed
      Site RO40002
      Bucuresti, Romania, 021495
      Completed
      Site KR82001
      Seoul, Republic of Korea, 03722
      Completed
      Site PH63001
      Quezon City, Philippines, 1100
      Withdrawn
      Site CO57002
      Cali, Valle del Cauca, Colombia, 760032
      Completed
      Site JO96201
      Irbid, Jordan, 22110
      Withdrawn
      Site BE32002
      Gent, Belgium, 9000
      Completed
      Site HR38503
      Zagreb, Croatia, 10000
      Completed
      Site NO47001
      Bergen, Norway, 5021
      Withdrawn
      Site TW88602
      Taipei, Taiwan, Province of China, 10002
      Completed
      Site SK42101
      Bratislava, Slovakia, 83301
      Completed
      Site PL48003
      Gdansk, Poland, 80-952
      Completed
      Site RS38102
      Nis, Serbia
      Withdrawn
      Site AU61001
      Park Ville VIC, Australia, 3052
      Completed
      Site MY60002
      Kuala Lumpur, Malaysia, 50586
      Completed
      Site BE32004
      Edegem, Belgium, B-2650
      Completed
      Site MX52002
      Mexico City, Mexico, 06700
      Completed
      Site PL48002
      Warszawa, Poland, 04-730
      Completed
      Site TW88601
      New Taipei City, Taiwan, Province of China, 23142
      Completed
      Site KR82002
      Seoul, Republic of Korea, 110744
      Completed
      Site RO40001
      Bucuresti, Romania, 22328
      Completed
      Site AU61002
      Randwick, NSW, Australia, 2031
      Withdrawn
      Site SK42102
      Martin, Slovakia, 036 59
      Completed
      Site HR38501
      Zagreb, Croatia, 10000
      Completed
      Site BE32001
      Gent, Belgium, 9000
      Completed
      Site DK45002
      Copenhagen, Denmark, 2100
      Completed
      Site IL97202
      Jerusalem, Israel, 91090
      Completed
      Site MY60001
      Georgetown, Malaysia, 10990
      Completed
      Site TR90008
      Mersin, Turkey, 33343
      Completed
      Site TR90002
      Ankara, Turkey, 06100
      Completed
      Site RS38101
      Novi Sad, Serbia, 21000
      Completed
      Site LT37001
      Vilnius, Lithuania, LT-08406
      Completed
      Site JO96202
      Amman, Jordan, 11183

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?